Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07 août 2024 06h30 HE
|
Liquidia Corporation
Liquidia Corporation (NASDAQ: LQDA) today reported financial results for the second quarter ended June 30, 2024.
District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch
03 juin 2024 07h00 HE
|
Liquidia Corporation
Judge Andrews denied the motion for preliminary injunction filed by United Therapeutics that sought to block the launch of Liquidia’s YUTREPIA™.
Global Medical Inhaled Nitric Oxide Market Growth Projection: Aiming for USD 1,520 Million by 2030 with a 7.7% CAGR
18 sept. 2023 07h24 HE
|
Zion Market Research
Washington, DC, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Zion Market Research has published a new research report titled “Medical Inhaled Nitric Oxide Market By Product Type (Inhaled Nitric Oxide Delivery...
Cardiotonic Agents Market Size to Reach USD 4.5 Bn by 2031 Due to the Rise in Prevalence of Cardiovascular Diseases | TMR Study
03 avr. 2023 11h30 HE
|
Transparency Market Research
Wilmington, Delaware, United States, April 03, 2023 (GLOBE NEWSWIRE) -- According to the market study by Transparency Market Research, the global cardiotonic agents market was worth USD 732 Million...
Inhaled Nitric Oxide Market Size is projected to reach USD 1.54 Billion by 2030, growing at a CAGR of 8.4%: Straits Research
11 août 2022 16h00 HE
|
Straits Research
New York, United States, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Inhaled nitric oxide is a pulmonary vasodilator that considerably controls vascular muscle tone. It has emerged as a therapy for hypoxemic...
Pulmonary Hypertension Clinical Trials Pipeline Offers Promising Novel Treatment Options | DelveInsight
01 août 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Pulmonary Hypertension Clinical Trials Pipeline Offers Promising Novel Treatment Options | DelveInsight DelveInsight’s pulmonary hypertension...
Ferrer Announces Distribution Agreement With United Therapeutics for Treprostinil Inhalation Solution for Pulmonary Hypertension Associated With Interstitial Lung Disease
28 févr. 2022 06h00 HE
|
Ferrer
BARCELONA, Spain, Feb. 28, 2022 (GLOBE NEWSWIRE) -- In the run up to Rare Disease Day, which is held on 28 February, International pharmaceutical company Ferrer has strengthened its focus on...
Halo Biosciences Participating in BIO @ JPM and BIOTECH SHOWCASE™ During J.P. Morgan Week 2022
10 janv. 2022 08h00 HE
|
Halo Biosciences
SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Halo Biosciences, a clinical stage biopharmaceutical company today announced that its Chief Executive Officer, Anissa Kalinowski, MSc, MBA, will...
Nu-Med Plus Closely Monitoring Outcomes on Two New Human Clinical Trials Using Inhaled Nitric Oxide in Treatment of COVID-19
25 mars 2020 06h00 HE
|
Nu-Med Plus Inc.
SALT LAKE CITY, March 25, 2020 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB: NUMD), a medical device company which investigates and develops applications and devices for nitric oxide in the medical...
38th Annual International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions Kicks Off with the INTERHEART Study, Pulmonary Hypertension and Heart Attack Recovery Using LVADs
11 avr. 2018 06h50 HE
|
International Society for Heart & Lung Transplantation
NICE, France, April 11, 2018 (GLOBE NEWSWIRE) -- Researchers at the Alberta Transplant Applied Genomics Centre (ATAGC) at the University of Alberta in Edmonton, Canada presented results of The...